Nothing Special   »   [go: up one dir, main page]

OA09908A - Treatment of neoplastic disease with interleukin-10 - Google Patents

Treatment of neoplastic disease with interleukin-10

Info

Publication number
OA09908A
OA09908A OA60389A OA60389A OA09908A OA 09908 A OA09908 A OA 09908A OA 60389 A OA60389 A OA 60389A OA 60389 A OA60389 A OA 60389A OA 09908 A OA09908 A OA 09908A
Authority
OA
OAPI
Prior art keywords
interleukin
treatment
neoplastic disease
patient
effective amount
Prior art date
Application number
OA60389A
Other languages
English (en)
Inventor
Paulo J M Vieira
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of OA09908A publication Critical patent/OA09908A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA60389A 1991-01-16 1993-07-07 Treatment of neoplastic disease with interleukin-10 OA09908A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64134791A 1991-01-16 1991-01-16

Publications (1)

Publication Number Publication Date
OA09908A true OA09908A (en) 1994-09-15

Family

ID=24571976

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60389A OA09908A (en) 1991-01-16 1993-07-07 Treatment of neoplastic disease with interleukin-10

Country Status (18)

Country Link
EP (1) EP0567576B1 (ja)
JP (1) JP3260368B2 (ja)
KR (1) KR100207766B1 (ja)
AT (1) ATE116550T1 (ja)
AU (1) AU652030B2 (ja)
CA (1) CA2100553A1 (ja)
CZ (1) CZ282523B6 (ja)
DE (1) DE69201128T2 (ja)
DK (1) DK0567576T3 (ja)
ES (1) ES2068705T3 (ja)
FI (1) FI933193A (ja)
GR (1) GR3015510T3 (ja)
HK (1) HK192196A (ja)
HU (1) HU218598B (ja)
NO (1) NO310444B1 (ja)
OA (1) OA09908A (ja)
SK (1) SK279556B6 (ja)
WO (1) WO1992012725A1 (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106823A (en) 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
EP0801951A3 (en) * 1992-08-20 1998-05-20 Schering Corporation Novel uses of Il-4 and/or Il-10, and antibodies against the same
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
AU707019B2 (en) * 1994-01-20 1999-07-01 Schering Corporation Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
DE69534265T2 (de) 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
AU5827000A (en) * 1999-07-16 2001-02-05 Maria Teresa Bejarano Viral il-10 uses
WO2002026265A2 (en) 2000-09-29 2002-04-04 Schering Corporation Pegylated interleukin-10
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
JP5888980B2 (ja) 2008-12-17 2016-03-22 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． モノ−およびジ−ｐｅｇｉｌ１０の製造および用途
MX2015014438A (es) 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
EP3434277A1 (en) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
MX2017004983A (es) 2014-10-22 2017-11-13 Armo Biosciences Inc Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
JP7121496B2 (ja) 2015-05-28 2022-08-18 アルモ・バイオサイエンシーズ・インコーポレイテッド 癌治療で使用するためのペグ化インターロイキン－１０
EP3341012A4 (en) 2015-08-25 2019-03-20 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
DK0506836T3 (da) * 1989-12-20 1994-11-28 Schering Corp BCRF1 proteiner som inhibitorer for interferon-gamma

Also Published As

Publication number Publication date
DE69201128D1 (de) 1995-02-16
NO932570L (no) 1993-07-15
CZ141293A3 (en) 1994-01-19
HU218598B (hu) 2000-10-28
FI933193A0 (fi) 1993-07-14
WO1992012725A1 (en) 1992-08-06
CA2100553A1 (en) 1992-07-17
KR100207766B1 (ko) 1999-07-15
JPH06504785A (ja) 1994-06-02
ATE116550T1 (de) 1995-01-15
GR3015510T3 (en) 1995-06-30
HUT69962A (en) 1995-09-28
CZ282523B6 (cs) 1997-07-16
FI933193A (fi) 1993-07-14
AU652030B2 (en) 1994-08-11
SK74793A3 (en) 1995-03-08
JP3260368B2 (ja) 2002-02-25
HU9302066D0 (en) 1993-11-29
ES2068705T3 (es) 1995-04-16
SK279556B6 (sk) 1998-12-02
HK192196A (en) 1996-10-25
AU1261792A (en) 1992-08-27
NO932570D0 (no) 1993-07-15
EP0567576B1 (en) 1995-01-04
DE69201128T2 (de) 1995-05-24
EP0567576A1 (en) 1993-11-03
DK0567576T3 (da) 1995-06-12
NO310444B1 (no) 2001-07-09

Similar Documents

Publication Publication Date Title
HK192196A (en) Treatment of neoplastic disease with interleukin-10
EG19304A (en) Method of treating pre-menstrual syndrome
EP0553291A4 (en) Treatment of autoimmune diseases by oral administration of autoantigens
EP0359783A4 (en) TREATMENT OF AUTO-IMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTO-ANTIGENS.
ZA913282B (en) Dosage form
EP0292172A3 (en) Apparatus for thermal treatment of body tissue
EP0102534A3 (en) Hair-growing agent
IE900250L (en) Immunogenic compositions against gastrin peptides
KR890701107A (ko) 알쯔하이머 병 치료용 화합물들
GR3029670T3 (en) Treatment of macular degeneration.
HU891056D0 (en) Process for treating the diseases of the gullet and the stomach-intestine system
SG45366A1 (en) Method of treating and/or diagonising soft tissue tumors
PH24568A (en) Use of bezafibrate for treating diabetes
IL83775A0 (en) Fumaramide derivatives and pharmaceutical compositions containing them for treating skin diseases
MY104521A (en) Treatment of depression.
ES2117008T3 (es) Metodo de tratamiento con amperozida de la esquizofrenia resistente a la terapia.
PL277464A1 (en) Apparatus for surgical treatment of ametropia
HU900381D0 (en) Process for producing medical preparatives utilizable for treating cancerous diseases
ES2005926A6 (es) Aparato de estimulacion de la piel mediante una senal electromagnetica.
HUT64478A (en) Process for producing medical preparatives for treatment of b-cell tumours
PL283664A1 (en) Therapeutical set for treating limb bone fractures by traction
Shust 10-year results of programmed treatment of Hodgkin's disease patients
EP0267402A3 (en) Use of follicle regulatory protein for the production of a therapeutic agent for the treatment of neoplasm of gonadal origin
IT1243947B (it) 2-azido-ornitina, sua preparazione e suo impiego in terapia
RU93046326A (ru) Способ лечения медикаментозных эзофаго-гингиво-стоматитов